Table 1.
Summary of medications under investigation for HS currently recruiting or not yet recruiting
| Clinical trial no. | Clinical trial phase | Agent | Target/mechanism | Route of administration |
|---|---|---|---|---|
| NCT05355805 | 2b | Izokibep | IL-17A inhibitor | Subcutaneous |
| NCT05322473 | 2 | Sonelokimab | IL-17A and IL-17F inhibitor | Subcutaneous |
| NCT04179175 | 3 | Secukinumab | IL-17A inhibitor | Subcutaneous |
| NCT04246372 | 2 | Tofacitinib | JAK inhibitor | Oral |
| NCT05620823 | 3 | Povorcitinib | JAK inhibitor | Oral |
| NCT05620836 | 3 | Povorcitinib | JAK inhibitor | Oral |
| NCT04414514 | 2 | Ruxolitinib | JAK inhibitor | Topical |
| NCT05635838 | 2 | Ruxolitinib | JAK inhibitor | Topical |
| NCT05139602 | 2 | Lutikizumab | IL-1 inhibitor | Subcutaneous |
| NCT03827798 | 2 | Iscalimab | Anti-CD-40 monoclonal antibody | Subcutaneous |
| NCT03827798 | 2 | LYS006 | Leukotriene A4 inhibitor | Oral |
| NCT03827798 | 2 | MAS825 | IL-1β and IL-18 inhibitor | Subcutaneous |
| NCT03827798 | 2 | Remibrutinib | BTK inhibitor | Oral |
| NCT04989517 | 1 | AT193 | AHR agonist | Topical |
| NCT05040698 | 2 | Fostamatinib | Syk inhibitor | Oral |
| NCT05020730 | 2 | PTM-001 | Glycan-targeting antibody | Oral |
| NCT05348681 | 2a | RIST4721 | CXCR2 inhibitor | Oral |
| NCT04982432 | 2 | Orismilast | PDE4 inhibitor | Oral |
| NCT04649502 | 3 | Metformin and doxycycline | Antiinflammatory effects | Oral |
| NCT05103423 | 1/2 | BDB-001 | TLR7/8 agonist | Intravenous |
| NCT05286567 | 1 | RGRN-305 | HSP90 inhibitor | Oral |
IL interleukin, JAK Janus kinase, PDE4 Phosphodiesterase-4, BTK Bruton’s tyrosine kinase, AHR Aryl hydrocarbon receptor, Syk Spleen tyrosine kinase, CXCR2 Chemokine receptor 2, TLR7/8 Toll-like receptor 7/8, HSP90 Heat shock protein 90